Status
Conditions
Treatments
About
The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic. The main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Chronic tromboembolic pulmonary hypertesion in such a way as to ensure the maximum positive impact on the health of the population and high cost-effectiveness of the whole process.
Full description
The project is a national, prospective, multicenter, observational pilot project of screening CTEPH in pacients after APE in the Czech Republic.
The global goal of the project is to develop, test and implement a uniform procedure for early detection of patients with CTEPH and to set up a process for their rapid referral to a specialized center that treats chronic thromboembolic pulmonary hypertension. The timeliness of the treatment set up has a significant impact on patient's future quality of life and eliminates the risk of subsequent complications or death.
The main objective of this activity is to validate the CTEPH screening process, which will benefit 500 patients in approximately 10 selected centres. Subsequently, patient flow from the cardiologist to a specialised pulmonary hypertension treatment centre will be ensured. The process will include a review and evaluation of the screening algorithm in patients in the pilot.
The project is supported by the European Social Fund (Operational Program Employment plus) and the state budget of the Czech Republic and is registered by the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0002007
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age over 18 years
Signed consent to participate in the project and GDPR
Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy:
ECHO evidence of severe PH at diagnosis of PE (PASP >60 mmHg)
Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin)
Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems
Presence of ventriculoatrial shunt for treatment of hydrocephalus
Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease)
History of splenectomy
Myeloproliferative disorders
Chronic osteomyelitis
Exclusion criteria
500 participants in 1 patient group
Loading...
Central trial contact
Lucie Mandelová, PhD; Kateřina Ondrášková, Msc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal